Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 11;12:746643. doi: 10.3389/fonc.2022.746643

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Yang, Wang, Li, Gao, Fan and Wang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Relationships between the IL-6 promoter methylation level and quantitative clinical data in the HCC group. (A) The PMR value of the IL-6 promoter was not significantly correlated with ALT in patients with HCC (Spearman’s R = -0.052, P = 0.555). (B) The PMR value of the IL-6 promoter was significantly correlated with TBIL in patients with HCC (Spearman’s R = 0.186, P = 0.032). (C) The PMR value of the IL-6 promoter was significantly correlated with age in patients with HCC (Spearman’s R = 0.193, P = 0.026). (D) The PMR value of the IL-6 promoter was not significantly correlated with PT-INR in patients with HCC (Spearman’s R = -0.014, P = 0.873). (E) The PMR value of the IL-6 promoter was not significantly correlated with AST in patients with HCC (Spearman’s R = 0.043, P = 0.619). (F) The PMR value of the IL-6 promoter was not significantly correlated with PTA in patients with HCC (Spearman’s R = 0.017, P = 0.850). (G) The PMR value of the IL-6 promoter was not significantly correlated with AFP in patients with HCC (Spearman’s R = 0.041, P = 0.613). (H) The PMR value of the IL-6 promoter was not significantly correlated with ALB in patients with HCC (Spearman’s R =-0.032, P = 0.713).